Three cases of bortezomib-resistant multiple myeloma with extramedullary masses

Tokai Journal of Experimental and Clinical Medicine

Volumn 35, Issue 1, 2010, Pages 17-20

  Moriuchi, Makiko ^a   Ohmachi, Ken ^a   Kojima, Minoru ^a   Tsuboi, Kosuke ^a   Ogawa, Yoshiaki ^a   Nakamura, Naoya ^a   Ando, Kiyoshi ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bortezomib; Extramedullary mass; Multiple myeloma; Plasmacytoma; Treatment

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; M PROTEIN; MELPHALAN; PREDNISOLONE; VINCRISTINE;

ADULT; ARTICLE; AUTOPSY; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CASE REPORT; CYTOGENETICS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; KARYOTYPING; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA CELL; PLASMACYTOMA; RADIATION DOSE; TREATMENT RESPONSE;

BORONIC ACIDS; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES;

EID: 77952352537     PISSN: 03850005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol 1994; 12: 2398-404.
2. Blade J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996; 93: 345-351.
3. Raanani P, Shpilberg O, Ben-Bassat I. Extramedullary disease and targeted therapies for hematological malignancies--is the association real? Ann Oncol 2007; 18: 7-12.
4. Varettoni M, Mangiacavalli S, Zappasodi P, Pica GM, Lazzarino M, Corso A. Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas. Leuk Res 2008; 32: 839-841.
5. Patriarca F, Prosdocimo S, Tomadini V, Vasciaveo A, Bruno B, Fanin R. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica 2005; 90: 278-279.
6. Hughes M, Micallef-Eynaud P. Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas. Clin Lab Haematol 2006; 28: 267-269.
7. Rosinol L, Cibeira MT, Uriburu C, Yantorno S, Salamero O, Blade J et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 2006; 76: 405-408.
8. Ali R, Ozkalemkas F, Ozkan A, Ozkocaman V, Ozcelik T, Ozan U et al. Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon. Leuk Res 2007; 31: 1153-1155.
9. Pantelidou D, Tsatalas C, Margaritis D, Anastasiadis AG, Kaloutsi V, Argyropoulou P et al. Successful treatment of lymph node extramedullary plasmacytoma with bortezomib. Ann Hematol 2006; 85: 188-190.
10. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
11. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-2622.
12. Terpos E, Rezvani K, Basu S, Milne AE, Rose PE, Scott GL et al. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. Eur J Haematol 2005: 75: 376-383.
13. Alegre A, Granda A, Martinez-Chamorro C et al. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Haematologica 2002: 87: 609-614.
14. Sanal SM, Yaylaci M, Mangold KA, Pantazis CG. Extensive extramedullary disease in myeloma. An uncommon variant with features of poor prognosis and dedifferentiation. Cancer 1996; 77: 1298-1302.